Sahajanand Medical Technologies Approves Q2 FY27 Results & Invests in US-Based SNP Medical Corp.
Sahajanand Medical Technologies Limited approved its unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. The company's subsidiary will invest up to USD 7,80,000 in US-based SNP Medical Corp. to increase its stake to 17.19%, with completion targeted by March 31, 2027. M/s. Amit Jaste & Associates has been appointed as the Secretarial Auditor for five years.
The acquisition of a stake in a US-based medical device startup and the appointment of a secretarial auditor for a long term are significant strategic and operational developments for the company.
The announcement includes the approval of financial results and a strategic acquisition, indicating positive company performance and growth initiatives.
Sahajanand Medical Technologies Limited (SMT) announced the outcome of its Board Meeting held on November 05, 2026. The Board has approved the Unaudited Standalone and Consolidated Financial Results for the quarter and half-year ended September 30, 2026.
In a significant strategic move, SMT's wholly-owned subsidiary, Sahajanand Medical Technologies Ireland Limited, will invest in SNP Medical Corp., a US-based corporation registered in Delaware. This acquisition aims to diversify SMT's product portfolio within its existing main line of business in the medical device sector. SMT Ireland currently holds a 14.15% stake in SNP Medical Corporation, and this new investment will increase it to up to 17.19%. The acquisition cost is up to USD 7,80,000, with the price per share determined by SNP's valuation. SNP Medical Corp., a medical device startup, was incorporated on May 31, 2022, and reported revenues of USD 3,00,000 in 2025, USD 2,34,960 in 2024, and USD 5,64,930 in 2023. The acquisition is expected to be completed by March 31, 2027. Notably, Ms. Priyanka Cohen, a Promoter and Non-Executive Director of SMT, is also a Director in SNP, but the transaction is conducted on an arm's length basis.
Furthermore, the Board has approved the appointment of M/s. Amit Jaste & Associates as the Secretarial Auditor of the Company for a term of five consecutive financial years from FY 2026-27 to FY 2030-31, subject to shareholder approval. The board meeting commenced at 3:00 PM IST and concluded at 4:43 PM IST.
What to do with a filing like this
Sahajanand Medical Technologies Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sahajanand Medical Technologies Limited. Read the original for the full detail.